RespireRx Pharmaceuticals Inc (RSPI)

[atheroprevent]

Why does this board expect BP buyout after the ADHD FDA return of CX 717 IND. The current SP reflects greater risk or lower likelihood of NDA for ampakines. Prior to IND return by the FDA, BP buyout seemed rational. Now it is wishful thinking.

I think buyout is off the table for this year, at least until COR can demonstrate a marketable signal of benefit in humans from ampakine administration in RD or AD.

If the AD trial remains free of adverse effect and demonstrates some early benefits in memory formation, which would allow patients to be managed at home longer, ampakines would be developed as a blockbuster. The ADHD door would reopen, hopefully sooner than the years that Neuro suggested.

I would love to see the spotlight remain on Pirosh as he reverses his prediction again. I don't know how Havrilla responded. He had predicted the highest likelihood of success for the IND.

I join the COR club, at the gold level (50K or more) of charitable giving for ampakine development. I continue to hold all of my shares.

Biotech investing is becoming an oxymoron in today's regulatory environment.